Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662241 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
A Phase 3 study of IgG4 Related Disease, sponsored by Zenas BioPharma (USA).
- Active
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT05662241 is a Phase 3 study of IgG4 Related Disease that is active but no longer recruiting, run by Zenas BioPharma (USA). The registered enrollment target is 194 participants, above the 44-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (341% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT05662241, a Phase 3 study of IgG4 Related Disease, is active but no longer recruiting, sponsored by Zenas BioPharma (USA).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Obexelimab
Study Locations (20)
Beijing Municipality
- Chinese PLA General Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
- Peking University First Hospital - Beijing
California
- Stanford Medicine - Stanford
Florida
- GI PROS Research - Dedicated Research Facility - Naples
Georgia
- Emory Univeristy - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Hospital - Detroit
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
British Columbia
- Artus Health Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2029-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662241
The ClinicalTrials.gov registry entry for NCT05662241 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (341% higher). The listed sponsor is Zenas BioPharma (USA), which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgG4 Related Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05662241 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Beijing Municipality, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05662241 about?
NCT05662241 is a clinical study titled "A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease". This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
What is the current status of trial NCT05662241?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2023-01-09. Estimated completion is 2029-02-15.
What conditions does trial NCT05662241 study?
This clinical trial studies the following conditions: IgG4 Related Disease.
What interventions are being tested in trial NCT05662241?
The interventions under investigation include: Placebo (OTHER), Obexelimab (DRUG).
Who is sponsoring clinical trial NCT05662241?
This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662241 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
RECRUITING · Phase 1
-
A Study of Efgartigimod in Patients With IgG4-Related Disease
RECRUITING · Phase 2
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.